Oxidative Stress and Neuroprotection

Editors:

ISBN: 978-3-211-33327-3 (Print) 978-3-211-33328-0 (Online)

Table of contents (26 chapters)

previous Page of 2
  1. Front Matter

    Pages I-XIV

  2. No Access

    Book Chapter

    Pages 1-15

    Levodopa in the treatment of Parkinson’s disease

  3. No Access

    Book Chapter

    Pages 17-25

    Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole

  4. No Access

    Book Chapter

    Pages 27-30

    The DONPAD-study — Treatment of dementia in patients with Parkinson’s disease with donepezil

  5. No Access

    Book Chapter

    Pages 31-37

    PD-related psychosis: pathophysiology with therapeutical strategies

  6. No Access

    Book Chapter

    Pages 39-43

    Antioxidant capacity in postmortem brain tissues of Parkinson’s and Alzheimer’s diseases

  7. No Access

    Book Chapter

    Pages 45-51

    Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines — implications for the CNS

  8. No Access

    Book Chapter

    Pages 53-65

    Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells

  9. No Access

    Book Chapter

    Pages 67-77

    Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection

  10. No Access

    Book Chapter

    Pages 79-86

    The relationship of early studies of monoamine oxidase to present concepts

  11. No Access

    Book Chapter

    Pages 87-95

    Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson’s disease induced by the Japanese encephalitis virus

  12. No Access

    Book Chapter

    Pages 97-103

    Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl

  13. No Access

    Book Chapter

    Pages 105-112

    Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine

  14. No Access

    Book Chapter

    Pages 113-122

    Neuroprotection for Parkinson’s disease

  15. No Access

    Book Chapter

    Pages 123-132

    Marker for a preclinical diagnosis of Parkinson’s disease as a basis for neuroprotection

  16. No Access

    Book Chapter

    Pages 133-141

    Assessing neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo

  17. No Access

    Book Chapter

    Pages 143-156

    Deprenyl: from chemical synthesis to neuroprotection

  18. No Access

    Book Chapter

    Pages 157-161

    The use of rasagiline in Parkinson’s disease

  19. No Access

    Book Chapter

    Pages 163-172

    Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases

  20. No Access

    Book Chapter

    Pages 173-196

    Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain

  21. No Access

    Book Chapter

    Pages 197-200

    Long lasting effects of infancy iron deficiency — Preliminary results

previous Page of 2